Monoclonal Antibody Purification: 
A Two-Step Approach Using a Strong AEX-HIC Mixed-Mode Resin

Monoclonal antibodies (mAbs) increasingly comprise a large portion of the product pipeline of major biopharmaceutical companies. Challenges in mAb purification include reducing production cost, developing robust processes for both product purity and viral clearance, and integrating upstream and downstream processes. 

Traditional mAb purification platforms involve three chromatography steps: Protein A is first used to capture the product, followed by two additional chromatography steps to remove host-cell proteins, DNA, charged variants, and aggregates. 

Alternatively, well-optimized chromatography with Nuvia™ aPrime 4A Media, a mixed-mode resin, can eliminate an entire step of the process, resulting in a two-step strategy that considerably decreases production costs by reducing process time, buffer consumption, and media costs while increasing product yield. 

This 15-minute video describes how implementing such a two-step chromatography strategy can significantly reduce production costs and increase product yield in mAb purification. 

Speaker
Marian Magdy
R&D Purification Manager, Minapharm Pharmaceuticals

Marian Magdy is a biopharmaceutical professional with almost 16 years of experience in the industry. A pharmacy graduate in 2001, Marian began her career at the Central administration of Pharmaceutical affairs, where she worked until 2008. In 2009, she joined Minapharm as a downstream processing specialist in the research and development lab, advancing through the ranks to become the head of the downstream department starting in 2019. In 2025, she was promoted to be the manager of the department. Today, Marian leads the development of the downstream process of several projects, including monoclonal antibodies, hormones, and vaccines. She also contributed to the technology transfer and upscale of several projects to the commercial scale.